Procter & Gamble Health Ltd reported a consolidated net profit of Rs 885.4 million for the September 2025 quarter, with revenue from operations reaching Rs 3.25 billion. The company’s performance was driven by strong demand in its core healthcare portfolio and disciplined cost management across operations.
Steady Growth Anchored By Healthcare Demand
Procter & Gamble Health Ltd has announced its financial results for the second quarter of FY2025–26, showcasing a stable performance in a competitive healthcare market. The company recorded consolidated revenue of Rs 3.25 billion and a net profit of Rs 885.4 million for the quarter ended September 30, 2025.
The growth was supported by sustained demand for key products in the vitamins, minerals, and supplements category. Operational efficiencies and strategic pricing initiatives helped maintain profitability despite inflationary pressures and supply chain challenges.
Management emphasized continued investment in brand building, innovation, and digital outreach to strengthen consumer engagement. The company also reaffirmed its commitment to expanding its product portfolio and enhancing distribution networks across urban and semi-urban markets.
Major Takeaways
- Q2 FY2025–26 consolidated revenue: Rs 3.25 billion
- Net profit for the quarter: Rs 885.4 million
- Strong performance in core healthcare segments
- Focus on cost control and strategic pricing
- Continued investment in innovation and market expansion
Sources: Moneycontrol, INDmoney, Procter & Gamble Investor Relations